title: A new approach to managing oral manifestations of Sjogren's syndrome and skin manifestations of lupus.
abstract: Sjogren's syndrome (SS) is an autoimmune disorder that affects the salivary glands, leading to xerostomia, and the lacrimal glands, resulting in xerophthalmia. Secondary SS is associated with other autoimmune disorders such as systemic rheumatic diseases and systemic lupus erythematosis (SLE), which can affect multiple organs, including the epidermis. Recent studies have demonstrated that green tea polyphenols (GTPs) possess both anti-inflammatory and anti-apoptotic properties in normal human cells. Epidemiological evidence has indicated that, in comparison to the United States, the incidence of SS, clinical xerostomia and lupus is considerably lower in China and Japan, the two leading green tea-consuming countries.Thus, GTPs might be responsible, in part, for geographical differences in the incidence of xerostomia by reducing the initiation or severity of SS and lupus. Consistent with this, molecular, cellular and animal studies indicate that GTPs could provide protective effects against autoimmune reactions in salivary glands and skin. Therefore, salivary tissues and epidermal keratinocytes could be primary targets for novel therapies using GTPs. This review article evaluates the currently available research data on GTPs, focusing on their potential application in the treatment of the oral manifestations of SS and skin manifestations of SLE.
authors.affiliation: Department of Oral Biology and Maxillofacial Pathology, School of Dentistry, Medical College of Georgia, Augusta, USA. shsu@mail.mcg.edu
authors.forename: Stephen
authors.initials: S
authors.lastname: Hsu
authors.forename: Douglas
authors.initials: D
authors.lastname: Dickinson
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D028241:Camellia sinensis; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D020935:MAP Kinase Signaling System; D008297:Male; D008517:Phytotherapy; D012469:Salivary Glands / Q000166:cytology / Q000378:metabolism; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D013662:Tea; D014987:Xerostomia / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D013662:Tea; D002392:Catechin; C045651:epigallocatechin gallate